FDA Approves New Intravenous Monkeypox Drug Treatment From PFIZER-Linked SIGA Technologies – Nwo Report

Pfizer is apparently at it again, conveniently hitting another grand slam with another perfectly timed drug release for the latest viral outbreak sweeping the west – monkeypox.

On Thursday, the US Food and Drug Administration (FDA) announced that it had approved the company’s intravenous version of TPOXX® (tecovirimat) for use in the US to treat monkeypox. The new drug was created by SIGA Technologies, which formed a partnership related to the drug with Meridian Medical Technologies in 2019.

Their drug TPOXX has been available for use to treat smallpox for several years, but it was only available in pill form. The new version of TPOXX will be delivered directly into the bloodstream via injection and also reportedly works for treating monkeypox.

FDA Approves New Intravenous Monkeypox Drug Treatment From PFIZER-Linked SIGA Technologies – Nwo Report